Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention

American Heart Journal

Volumn 148, Issue 4, 2004, Pages 670-675

  Rahel, Braim M ^a   Visseren, Frank L J ^a   Suttorp, Maarten Jan ^a   Plokker, Thijs H W ^a   Kelder, Johannes C ^a   De Jongh, Bartelt M ^b   Diepersloot, Rob J A ^c   Verkooyen, Roel P A J ^d   Bouter, K Paul ^e  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACTERIAL INFECTION; CALCULATION; CHLAMYDOPHILA PNEUMONIAE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; CYTOMEGALOVIRUS; DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; VIRUS INFECTION;

ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY BYPASS; CORONARY DISEASE; CORONARY RESTENOSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RECURRENCE;

EID: 5344247904     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.04.018     Document Type: Article

References (26)

1. Adam E., Melnick J.L., Probtsfield J.L., et al. High level of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet. 2:1987;291-293
2. Epstein S.E., Speir E., Zhou Y.F., et al. The role of infection in restenosis and atherosclerosis focus on cytomegalovirus. Lancet. 348:1996;13-17
3. Blum A., Giladi M., Weinberg W., et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol. 81:1998;866-868
4. Rassu M., Cazzavillan S., Scagnelli M., et al. Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions. Atherosclerosis. 158:2001;73-79
5. Tutuncu N.B., Guvener N., Tutuncu T., et al. Chlamydia pneumonia seropositivity correlates with serum fibrinogen and lipoprotein a levels any role in atherosclerosis? Endocr J. 48:2001;269-274
6. Rutherford J.D. Chlamydia pneumoniae and atherosclerosis. Curr Atheroscler Rep. 2:2000;218-225
7. Krüll M., Klucken A.D., Wuppermann F.N., et al. Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J Immunol. 162:1999;4834-4841
8. Dechend R., Maass M., Gieffers J., et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression. A potential link to accelerated arteriosclerosis. Circulation. 100:1999;1369-1373
9. Speir E., Modali R., Huang E.S., et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 165:1994;391-394
10. Tanaka K., Zou J.P., Takeda K., et al. Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation. 99:1999;1656-1659
11. Neumann F.J., Kastrati A., Miethke T., et al. Previous Cytomegalovirus infection and restenosis after coronary stent placement. Circulation. 104:2001;1135-1139
12. Manegold C., Alwazzeh M., Jablonowski H., et al. Prior cytomegalovirus infection and the risk of restenosis after percutaneous transluminal coronary balloon angioplasty. Circulation. 99:1999;1290-1294
13. Carlsson J., Miketic S., Mueller K.H., et al. Previous cytomegalovirus or Chlamydia pneumoniae infection and risk of restenosis after percutaneous transluminal coronary angioplasty. Lancet. 350:1997;1225
14. Schiele F., Batur M.K., Seronde M.F., et al. Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent implantation an angiographic and intravascular ultrasound study. Heart. 85:2001;304-311
15. Hoymans V.Y., Bosmans J.M., Van Renterghem L., et al. Importance of methodology in determination of Chlamydia pneumoniae seropositivity in healthy subjects and in patients with coronary atherosclerosis. J Clin Microbiol. 41:2003;4049-4053
16. Bertrand M.E., Bauters C. Cytomegalovirus infection and coronary restenosis. Circulation. 99:1999;1278-1279
17. Visseren F.L.J., Bouwman J.J.M., Bouter K.P., et al. Procoagulant activity of endothelial cells after infection with respiratory viruses. Thromb Haemost. 84:2000;319-324
18. Zhou Y.F., Leon M.B., Waclawiw M.A., et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 335:1996;624-630
19. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 340:1999;115-126
20. Fryer R.H., Schwobe E.P., Woods M.L., et al. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med. 45:1997;168-174
21. Dechend R., Maass M., Gieffers J., et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression a potential link to accelerated arteriosclerosis. Circulation. 100:1999;1369-1373
22. Zhou Y.F., Csako G., Grayston J.T., et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol. 84:1999;595-598
23. Neumann F.J., Kastrati A., Miethke T., et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3) a randomised, double-blind, placebo-controlled trial. Lancet. 357:2001;2085-2089
24. Muhlestein J.B., Anderson J.L., Carlquist J.F., et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation. 102:2000;1755-1760
25. Espinola-Klein C., Rupprecht H.J., Blankenberg S., et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 105:2002;15-21
26. Horne B.D., Muhlestein J.B., Strobel G.G., et al. Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. Am Heart J. 144:2002;491-500